Research Output per year
Publications
Article
Acquired tumor cell resistance to sunitinib causes resistance in a HT-29 human colon cancer xenograft mouse model without affecting sunitinib biodistribution or the tumor microvasculature
Gotink, K. J., Broxterman, H. J., Honeywell, R. J., Dekker, H., de Haas, R. R., Miles, K. M., Adelaiye, R., Griffioen, A. W., Peters, G. J., Pili, R. & Verheul, H. M. W., 2014, In : Oncoscience. 1, 12, p. 844-853 10 p.Research output: Contribution to journal › Article
21
Scopus
citations
Active ageing and success: A brief history of conceptual models
Petretto, D. R., Pili, R., Gaviano, L., Matos López, C. & Zuddas, C., Nov 28 2014, (Accepted/In press) In : Revista Espanola de Geriatria y Gerontologia.Research output: Contribution to journal › Article
9
Scopus
citations
Active smokingmay negatively affect response rate, progression-free survival, and overall survival of patients with metastatic renal cell carcinoma treatedwith sunitinib
Keizman, D., Gottfried, M., Ish-Shalom, M., Maimon, N., Peer, A., Neumann, A., Hammers, H., Eisenberger, M. A., Sinibaldi, V., Pili, R., Hayat, H., Kovel, S., Sella, A., Boursi, B., Weitzen, R., Mermershtain, W., Rouvinov, K., Berger, R. & Carducci, M. A., Jan 22 2014, In : Oncologist. 19, 1, p. 51-60 10 p.Research output: Contribution to journal › Article
32
Scopus
citations
Adenovirus-mediated gene transfer of fibroblast growth factor-1: Angiogenesis and tumorigenicity in nude mice
Pili, R., Chang, J., Muhlhauser, J., Crystal, R. G., Capogrossi, M. C. & Passaniti, A., Oct 29 1997, In : International Journal of Cancer. 73, 2, p. 258-263 6 p.Research output: Contribution to journal › Article
6
Scopus
citations
Adenovirus‐mediated gene transfer of wild‐type p53 results in melanoma cell apoptosis in vitro and in vivo
Cirielli, C., Riccioni, T., Yang, C., Pili, R., Gloe, T., Chang, J., Inyaku, K., Passaniti, A. & Capogrossi, M. C., Nov 27 1995, In : International Journal of Cancer. 63, 5, p. 673-679 7 p.Research output: Contribution to journal › Article
60
Scopus
citations
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): A double-blind, placebo-controlled, randomised, phase 3 trial
Haas, N. B., Manola, J., Uzzo, R. G., Flaherty, K. T., Wood, C. G., Kane, C., Jewett, M., Dutcher, J. P., Atkins, M. B., Pins, M., Wilding, G., Cella, D., Wagner, L., Matin, S., Kuzel, T. M., Sexton, W. J., Wong, Y. N., Choueiri, T. K., Pili, R., Puzanov, I. & 5 others, , May 14 2016, In : The Lancet. 387, 10032, p. 2008-2016 9 p.Research output: Contribution to journal › Article
283
Scopus
citations
A functional bioassay to determine the activity of anti-VEGF antibody therapy in blood of patients with cancer
Wentink, M. Q., Broxterman, H. J., Lam, S. W., Boven, E., Walraven, M., Griffioen, A. W., Pili, R., Van Der Vliet, H. J., De Gruijl, T. D. & Verheul, H. M. W., Oct 11 2016, In : British Journal of Cancer. 115, 8, p. 940-948 9 p.Research output: Contribution to journal › Article
1
Scopus
citations
A functional ryanodine-sensitive intracellular Ca2+ store is present in vascular endothelial cells
Ziegelstein, R. C., Spurgeon, H. A., Pili, R., Passaniti, A., Cheng, L., Corda, S., Lakatta, E. G. & Capogrossi, M. C., Jan 1 1994, In : Circulation research. 74, 1, p. 151-156 6 p.Research output: Contribution to journal › Article
Open Access
47
Scopus
citations
A liquid chromatography/tandem mass spectrometry assay to quantitate MS-275 in human plasma
Zhao, M., Rudek, M. A., Mnasakanyan, A., Hartke, C., Pili, R. & Baker, S. D., Jan 17 2007, In : Journal of Pharmaceutical and Biomedical Analysis. 43, 2, p. 784-787 4 p.Research output: Contribution to journal › Article
11
Scopus
citations
Alterations in chromatin accessibility and DNA methylation in clear cell renal cell carcinoma
Buck, M. J., Raaijmakers, L. M., Ramakrishnan, S., Wang, D., Valiyaparambil, S., Liu, S., Nowak, N. J. & Pili, R., Oct 9 2014, In : Oncogene. 33, 41, p. 4961-4965 5 p.Research output: Contribution to journal › Article
11
Scopus
citations
Altered angiogenesis underlying age-dependent changes in tumor growth
Pili, R., Guo, Y., Chang, J., Nakanishi, H., Martin, G. R. & Passaniti, A., Sep 7 1994, In : Journal of the National Cancer Institute. 86, 17, p. 1303-1314 12 p.Research output: Contribution to journal › Article
110
Scopus
citations
Androgen Receptor Modulation Optimized for Response (ARMOR) phase i and II studies: Galeterone for the treatment of castration-resistant prostate cancer
Montgomery, B., Eisenberger, M. A., Rettig, M. B., Chu, F., Pili, R., Stephenson, J. J., Vogelzang, N. J., Koletsky, A. J., Nordquist, L. T., Edenfield, W. J., Mamlouk, K., Ferrante, K. J. & Taplin, M. E., Mar 15 2016, In : Clinical Cancer Research. 22, 6, p. 1356-1363 8 p.Research output: Contribution to journal › Article
48
Scopus
citations
A new high affinity technetium-99m-bombesin analogue with low abdominal accumulation
Lin, K. S., Luu, A., Baidoo, K. E., Hashemzadeh-Gargari, H., Chen, M. K., Brenneman, K., Pili, R., Pomper, M., Carducci, M. A. & Wagner, H. N., Jan 1 2005, In : Bioconjugate Chemistry. 16, 1, p. 43-50 8 p.Research output: Contribution to journal › Article
56
Scopus
citations
A new high affinity technetium analogue of bombesin containing DTPA as a pharmacokinetic modifier
Lin, K. S., Luu, A., Baidoo, K. E., Hashemzadeh-Gargari, H., Chen, M. K., Pili, R., Pomper, M., Carducci, M. & Wagner, H. N., Nov 1 2004, In : Bioconjugate Chemistry. 15, 6, p. 1416-1423 8 p.Research output: Contribution to journal › Article
19
Scopus
citations
Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: A retrospective examination
Keizman, D., Huang, P., Eisenberger, M. A., Pili, R., Kim, J. J., Antonarakis, E. S., Hammers, H. & Carducci, M. A., Sep 1 2011, In : European Journal of Cancer. 47, 13, p. 1955-1961 7 p.Research output: Contribution to journal › Article
83
Scopus
citations
An open-label study to determine the maximum tolerated dose of the multitargeted tyrosine kinase inhibitor CEP-11981 in patients with advanced cancer
Pili, R., Carducci, M., Brown, P. & Hurwitz, H., Dec 1 2014, In : Investigational New Drugs. 32, 6, p. 1258-1268 11 p.Research output: Contribution to journal › Article
4
Scopus
citations
Antitumor activity and mechanistic characterization of APE1/ReF-1 inhibitors in bladder cancer
Fishel, M. L., Xia, H., McGeown, J., McIlwain, D. W., Elbanna, M., Craft, A. A., Kaimakliotis, H. Z., Sandusky, G. E., Zhang, C., Pili, R., Kelley, M. R. & Jerde, T. J., 2019, In : Molecular cancer therapeutics. 18, 11, p. 1947-1960 14 p.Research output: Contribution to journal › Article
Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models
Qian, D. Z., Wei, Y. F., Wang, X., Kato, Y., Cheng, L. & Pili, R., Aug 1 2007, In : Prostate. 67, 11, p. 1182-1193 12 p.Research output: Contribution to journal › Article
50
Scopus
citations
Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma
Kato, Y., Salumbides, B. C., Wang, X. F., Qian, D. Z., Williams, S., Wei, Y., Sanni, T. B., Atadja, P. & Pili, R., Jan 1 2007, In : Molecular cancer therapeutics. 6, 1, p. 70-81 12 p.Research output: Contribution to journal › Article
46
Scopus
citations
A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancer
Morris, M. J., Eisenberger, M. A., Pili, R., Denmeade, S. R., Rathkopf, D., Slovin, S. F., Farrelly, J., Chudow, J. J., Vincent, M., Scher, H. I. & Carducci, M. A., Oct 1 2012, In : Annals of Oncology. 23, 10, p. 2714-2719 6 p., mds078.Research output: Contribution to journal › Article
27
Scopus
citations
A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors
Michaelson, M. D., Gupta, S., Agarwal, N., Szmulewitz, R., Powles, T., Pili, R., Bruce, J. Y., Vaishampayan, U., Larkin, J., Rosbrook, B., Wang, E., Murphy, D., Wang, P., Lechuga, M. J., Valota, O. & Shepard, D. R., Sep 1 2019, In : Oncologist. 24, 9, p. 1151-e817Research output: Contribution to journal › Article
Open Access
A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer
Pili, R., Qin, R., Flynn, P. J., Picus, J., Millward, M., Ho, W. M., Pitot, H., Tan, W., Miles, K. M., Erlichman, C. & Vaishampayan, U., Dec 1 2013, In : Clinical Genitourinary Cancer. 11, 4, p. 477-483 7 p.Research output: Contribution to journal › Article
49
Scopus
citations
A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal ® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC)
Harrison, M. R., Hahn, N. M., Pili, R., Oh, W. K., Hammers, H., Sweeney, C., Kim, K. M., Perlman, S., Arnott, J., Sidor, C., Wilding, G. & Liu, G., Dec 1 2011, In : Investigational New Drugs. 29, 6, p. 1465-1474 10 p.Research output: Contribution to journal › Article
63
Scopus
citations
A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate
Bruce, J. Y., Eickhoff, J., Pili, R., Logan, T., Carducci, M., Arnott, J., Treston, A., Wilding, G. & Liu, G., Apr 2012, In : Investigational New Drugs. 30, 2, p. 794-802 9 p.Research output: Contribution to journal › Article
50
Scopus
citations
A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer
Heath, E. I., Gaskins, M., Pitot, H. C., Pili, R., Tan, W., Marschke, R., Liu, G., Hillman, D., Sarkar, F., Sheng, S., Erlichman, C. & Ivy, P., Sep 2005, In : Clinical Prostate Cancer. 4, 2, p. 138-141 4 p.Research output: Contribution to journal › Article
48
Scopus
citations
A Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer
Heath, E. I., Hillman, D. W., Vaishampayan, U., Sheng, S., Sarkar, F., Harper, F., Gaskins, M., Pitot, H. C., Tan, W., Ivy, S. P., Pili, R., Carducci, M. A., Erlichman, C. & Liu, G., Dec 1 2008, In : Clinical Cancer Research. 14, 23, p. 7940-7946 7 p.Research output: Contribution to journal › Article
137
Scopus
citations
A Phase II Trial of Temozolomide and IFN-α in Patients with Advanced Renal Cell Carcinoma
Sunkara, U., Walczak, J. R., Summerson, L., Rogers, T., Eisenberger, M., Denmeade, S., Pili, R., Huff, C. A., Sinibaldi, V. & Carducci, M. A., Jan 1 2004, In : Journal of Interferon and Cytokine Research. 24, 1, p. 37-41 5 p.Research output: Contribution to journal › Article
10
Scopus
citations
A Phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone
Resta, L. P., Pili, R., Eisenberger, M. A., Spitz, A., King, S., Porter, J., Franke, A., Boinpally, R., Carducci, M. A. & Sweeney, C. J., Feb 1 2011, In : Cancer Chemotherapy and Pharmacology. 67, 2, p. 431-438 8 p.Research output: Contribution to journal › Article
1
Scopus
citations
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of Aflibercept in Patients With Metastatic Renal Cell Carcinoma (ECOG-ACRIN [E4805])
Pili, R., Jegede, O., Carducci, M. A., Manola, J., Groteluschen, D. L., Appleman, L. L., Liu, G., Shanks, J. C., Dakhil, S. R., Dutcher, J. & DiPaola, R. S., Dec 2017, In : Clinical Genitourinary Cancer. 15, 6, p. 642-651.e1Research output: Contribution to journal › Article
Assay, isolation and characterization of circulating immune complexes from serum of gastrointestinal cancer, stage iii and iv melanoma and chronic inflammatory bowel disease patients
Bartoloni, C., Guidi, L., Pili, R., Lewis, Z. A., Tricerri, A., Cursi, F., Gentiioni, N., Cortesi, E. & Gambassi, G., Jan 1 1987, In : Oncology (Switzerland). 50, 1, p. 27-34 8 p.Research output: Contribution to journal › Article
7
Scopus
citations
Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC)1A.J.A. and R.K. contributed equally to this work
Armstrong, A. J., Kaboteh, R., Carducci, M. A., Damber, J. E., Stadler, W. M., Hansen, M., Edenbrandt, L., Forsberg, G., Nordle, Ö., Pili, R. & Morris, M. J., Jan 1 2014, In : Urologic Oncology: Seminars and Original Investigations. 32, 8, p. 1308-1316 9 p.Research output: Contribution to journal › Article
34
Scopus
citations
Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma
Keizman, D., Ish-Shalom, M., Pili, R., Hammers, H., Eisenberger, M. A., Sinibaldi, V., Boursi, B., Maimon, N., Gottfried, M., Hayat, H., Peer, A., Kovel, S., Sella, A., Berger, R. & Carducci, M. A., May 1 2012, In : European Journal of Cancer. 48, 7, p. 1031-1037 7 p.Research output: Contribution to journal › Article
42
Scopus
citations
CEP-7055: A novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models
Ruggeri, B., Singh, J., Gingrich, D., Angeles, T., Albom, M., Chang, H., Robinson, C., Hunter, K., Dobrzanski, P., Jones-Bolin, S., Aimone, L., Klein-Szanto, A., Herbert, J. M., Bono, F., Schaeffer, P., Casellas, P., Bourie, B., Pili, R., Isaacs, J., Ator, M. & 4 others, , Sep 15 2003, In : Cancer Research. 63, 18, p. 5978-5991 14 p.Research output: Contribution to journal › Article
110
Scopus
citations
Class I histone deacetylase inhibition is a novel mechanism to target regulatory T cells in immunotherapy
Shen, L. & Pili, R., Dec 1 2012, In : OncoImmunology. 1, 6, p. 948-950 3 p.Research output: Contribution to journal › Article
21
Scopus
citations
Class I Histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models
Shen, L., Ciesielski, M., Ramakrishnan, S., Miles, K. M., Ellis, L., Sotomayor, P., Shrikant, P., Fenstermaker, R. & Pili, R., Jan 27 2012, In : PloS one. 7, 1, e30815.Research output: Contribution to journal › Article
92
Scopus
citations
Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1α
Qian, D. Z., Kachhap, S. K., Collis, S. J., Verheul, H. M. W., Carducci, M. A., Atadja, P. & Pili, R., Sep 1 2006, In : Cancer Research. 66, 17, p. 8814-8821 8 p.Research output: Contribution to journal › Article
239
Scopus
citations
Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers
Radovich, M., Kiel, P. J., Nance, S. M., Niland, E. E., Parsley, M. E., Ferguson, M. E., Jiang, G., Ammakkanavar, N. R., Einhorn, L. H., Cheng, L., Nassiri, M., Davidson, D. D., Rushing, D. A., Loehrer, P. J., Pili, R., Hanna, N., Thomas Callaghan, J., Skaar, T. C., Helft, P. R., Shahda, S. & 2 others, , 2016, In : Oncotarget. 7, 35, p. 56491-56500 10 p.Research output: Contribution to journal › Article
38
Scopus
citations
Collecting duct carcinoma of the kidney is associated with CDKN2A deletion and SLC family gene up-regulation
Wang, J., Papanicolau-Sengos, A., Chintala, S., Wei, L., Liu, B., Hu, Q., Miles, K. M., Conroy, J. M., Glenn, S. T., Costantini, M., Magi-Galluzzi, C., Signoretti, S., Choueiri, T., Gallucci, M., Sentinelli, S., Fazio, V. M., Poeta, M. L., Liu, S., Morrison, C. & Pili, R., May 24 2016, In : Oncotarget. 7, 21, p. 29901-29915 15 p.Research output: Contribution to journal › Article
19
Scopus
citations
Combination of HDAC inhibitor MS-275 and IL-2 increased anti-tumor effect in a melanoma model via activated cytotoxic T cells
Kato, Y., Yoshino, I., Egusa, C., Maeda, T., Pili, R. & Tsuboi, R., Aug 2014, In : Journal of Dermatological Science. 75, 2, p. 140-147 8 p.Research output: Contribution to journal › Article
14
Scopus
citations
Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis
Pili, R., Kruszewski, M. P., Hager, B. W., Lantz, J. & Carducci, M. A., Feb 15 2001, In : Cancer Research. 61, 4, p. 1477-1485 9 p.Research output: Contribution to journal › Article
114
Scopus
citations
Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: A multicentre, single-arm phase I/II clinical trial
Pili, R., Liu, G., Chintala, S., Verheul, H., Rehman, S., Attwood, K., Lodge, M. A., Wahl, R., Martin, J. I., Miles, K. M., Paesante, S., Adelaiye, R., Godoy, A., King, S., Zwiebel, J. & Carducci, M. A., Mar 28 2017, In : British Journal of Cancer. 116, 7, p. 874-883 10 p.Research output: Contribution to journal › Article
29
Scopus
citations
Combination strategy targeting the hypoxia inducible factor-1 α with mammalian target of rapamycin and histone deacetylase inhibitors
Verheul, H. M. W., Salumbides, B., Van Erp, K., Hammers, H., Qian, D. Z., Sanni, T., Atadja, P. & Pili, R., Jun 1 2008, In : Clinical Cancer Research. 14, 11, p. 3589-3597 9 p.Research output: Contribution to journal › Article
95
Scopus
citations
Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models
Ciamporcero, E., Miles, K. M., Adelaiye, R., Ramakrishnan, S., Shen, L., Ku, S. Y., Pizzimenti, S., Sennino, B., Barrera, G. & Pili, R., Jan 1 2015, In : Molecular cancer therapeutics. 14, 1, p. 101-110 10 p.Research output: Contribution to journal › Article
54
Scopus
citations
Combinatorial antitumor effect of HDACs and the PI3K-Akt-mTOR pathway inhibition in a Pten deficient model of prostate cancer
Ellis, L., Ku, S. Y., Ramakrishnan, S., Lasorsa, E., Azabdaftari, G., Godoy, A. & Pili, R., Dec 2013, In : Oncotarget. 4, 12, p. 2225-2236 12 p.Research output: Contribution to journal › Article
Open Access
47
Scopus
citations
Concordance of cancer patients' function, symptoms, and supportive care needs
Snyder, C. F., Garrett-Mayer, E., Blackford, A. L., Brahmer, J. R., Carducci, M. A., Pili, R., Stearns, V., Wolff, A. C., Dy, S. M. & Wu, A. W., Oct 1 2009, In : Quality of Life Research. 18, 8, p. 991-998 8 p.Research output: Contribution to journal › Article
31
Scopus
citations
Concurrent HDAC and mTORC1 inhibition attenuate androgen receptor and hypoxia signaling associated with alterations in MicroRNA expression
Ellis, L., Lehet, K., Ramakrishnan, S., Adelaiye, R., Miles, K. M., Wang, D., Liu, S., Atadja, P., Carducci, M. A. & Pili, R., Nov 7 2011, In : PLoS ONE. 6, 11, e27178.Research output: Contribution to journal › Article
14
Scopus
citations
Contrasting effects of sunitinib within in vivo models of metastasis
Welti, J. C., Powles, T., Foo, S., Gourlaouen, M., Preece, N., Foster, J., Frentzas, S., Bird, D., Sharpe, K., Weverwijk, A. V., Robertson, D., Soffe, J., Erler, J. T., Pili, R., Springer, C. J., Mather, S. J. & Reynolds, A. R., Jul 30 2012, In : Angiogenesis. 15, 4, p. 623-641 19 p.Research output: Contribution to journal › Article
41
Scopus
citations
Crosstalk between Nrf2 and YAP contributes to maintaining the antioxidant potential and chemoresistance in bladder cancer
Ciamporcero, E., Daga, M., Pizzimenti, S., Roetto, A., Dianzani, C., Compagnone, A., Palmieri, A., Ullio, C., Cangemi, L., Pili, R. & Barrera, G., Feb 1 2018, In : Free Radical Biology and Medicine. 115, p. 447-457 11 p.Research output: Contribution to journal › Article
23
Scopus
citations
Decitabine, a DNA-demethylating agent, promotes differentiation via NOTCH1 signaling and alters immune-related pathways in muscle-invasive bladder cancer
Ramakrishnan, S., Hu, Q., Krishnan, N., Wang, D., Smit, E., Granger, V., Rak, M., Attwood, K., Johnson, C., Morrison, C., Pili, R., Chatta, G., Guru, K., Gueron, G., McNally, L., Wang, J. & Woloszynska-Read, A., Dec 1 2017, In : Cell Death and Disease. 8, 12, 3217.Research output: Contribution to journal › Article
5
Scopus
citations
Development of a castrate resistant transplant tumor model of prostate cancer
Ellis, L., Lehet, K., Ramakrishnan, S., Adelaiye, R. & Pili, R., May 1 2012, In : Prostate. 72, 6, p. 587-591 5 p.Research output: Contribution to journal › Article
11
Scopus
citations